AUSTRALIAN EMPLOYMENT & TRAINING GROUP PTY LTD
Clinical Trials
4
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
News
Mobile App OTX-202 Reduces Suicide Attempts by 58% in High-Risk Psychiatric Patients
A randomized controlled trial of 339 psychiatric inpatients found that the OTX-202 mobile app reduced post-discharge suicide attempts by 58.3% among patients with previous suicide attempts.
Neumora Therapeutics Initiates Phase 1 Trial of Novel M4 Receptor Modulator NMRA-861 for Schizophrenia
Neumora Therapeutics has initiated a Phase 1 single-ascending dose/multiple-ascending dose study of NMRA-861, a highly potent and selective positive allosteric modulator of the M4 muscarinic receptor for schizophrenia treatment.
Trump Administration Suspends Enforcement of Mental Health Parity Rule, Raising Concerns Over Treatment Access
The Trump administration has suspended enforcement of updated Mental Health Parity and Addiction Equity Act regulations that were finalized in September 2024 under the Biden administration.
Symptom Screening Tool Improves Supportive Care for Pediatric Cancer Patients
Two clinical trials demonstrated that using the SSPedi tool, which allows young cancer patients to report their symptoms, leads to improved supportive care and reduced side effects.
Community Trial to Assess Early Start Denver Model (ESDM) for Young Children with Autism
A cluster randomized controlled trial will compare the effectiveness of the Early Start Denver Model (ESDM) versus usual early behavioral intervention (EBI) for young children with autism.
Enhanced TSOS Intervention Shows Promise for Trauma Survivors in Australia
Researchers in Australia assessed the feasibility of an enhanced TSOS intervention for trauma patients at risk of persistent PTSD and pain.
AI and Behavioral Data to Predict Mental Health Treatment Outcomes in Young Adults
Mount Sinai and IBM Research are collaborating on the PREDiCTOR study to predict mental health treatment outcomes using AI and behavioral data.
High Adderall Doses Linked to Increased Psychosis Risk, Study Finds
A new study links high doses of Adderall (above 40mg) to a fivefold increased risk of first-time psychosis or mania episodes, particularly in young adults.